ACT | Jotup

Superdry plc: DIS-Disposal

Retrieved on:

Wednesday, March 22, 2023

The Agreement means Cowell will own and use the Superdry brand in key APAC markets, starting with its home market of South Korea and extending to others including China, with Superdry and Cowell working together to develop products relevant for those markets.

Key Points:

The Agreement means Cowell will own and use the Superdry brand in key APAC markets, starting with its home market of South Korea and extending to others including China, with Superdry and Cowell working together to develop products relevant for those markets.
Superdry will provide certain support and know-how relating to the Superdry brand to Cowell during the first two years following completion of the Sale.
In addition, the Agreement includes provisions granting Superdry a perpetual, irrevocable, and sub-licensable licence to enable Superdry to continue manufacturing (or engaging third parties to manufacture) goods in the APAC region.
The Agreement contemplates the intention of Superdry and Cowell to enter into an ancillary arrangement under which Superdry may purchase, and Cowell may supply, certain finished products.

JMIR RESEARCH PROTOCOLS | WHAT IS THE ROLE OF HUMAN DECISION-MAKING IN AN AI-DRIVEN FUTURE IN HEALTH?

Retrieved on:

Tuesday, March 21, 2023

TORONTO and PHILADELPHIA, March 21, 2023 /PRNewswire/ -- Australian researchers have established a set of protocols for a research project in JMIR Research Protocols that aims to explore whether humans will continue in meaningful decision-making roles in an AI-driven future. The researchers, Dr Nandini Doreswamy and Dr Louise Horstmanshof from Southern Cross University, found that there is a dearth of guidance in establishing whole sets of protocols for methods used in complex health research.

Key Points:

TORONTO and PHILADELPHIA, March 21, 2023 /PRNewswire/ -- Australian researchers have established a set of protocols for a research project in JMIR Research Protocols that aims to explore whether humans will continue in meaningful decision-making roles in an AI-driven future.
They have now established protocols that focus on non-clinical health services such as health regulation and health policy.
These health services can be complex, the researchers say, and even more extensive in their scope and scale than clinical healthcare.
During the pandemic, these services formed a continuum of rules, laws, and public health measures that varied from country to country.

Deepfactor Integrates SBOM Production, Operations, and Consumption to Help Businesses Comply with Supply Chain Security Executive Order Deadline

Retrieved on:

Tuesday, March 21, 2023

ACT, NIST, SDLC, SPDX, Unitary state, Gartner, SBOM, Government, Organization, Federation, Software, National Institute of Standards and Technology, European, SAN, OMB, Medical device, EU

These capabilities will enable businesses to improve supply chain security and comply with the June 2023 deadline set by the U.S. Federal Government.

Key Points:

These capabilities will enable businesses to improve supply chain security and comply with the June 2023 deadline set by the U.S. Federal Government.
According to the 2023 Gartner® report, 'Innovation Insight for SBOMs', “SBOMs help organizations to determine if they are susceptible to security vulnerabilities previously identified in software components.
Security conscious private companies are also following suit and incorporating SBOMs into their software procurement processes to improve supply chain security.
The Deepfactor portal provides a searchable and filterable human-readable interface to help security teams quickly respond to zero-day vulnerabilities, developers to fix vulnerabilities, and customers to verify the supply chain security of their software.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on:

Tuesday, March 21, 2023

ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points:

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
Owner or controller of interests and short positions disclosed, if different from 1(a)
The naming of nominee or vehicle companies is insufficient.
For a trust, the trustee(s), settlor and beneficiaries must be named.
If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
For an opening position disclosure, state the latest practicable date prior to the disclosure
In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

RevoluGROUP Canada Inc. Equity Investment Suitor Adjusts Timeline Reaffirming Commitment

Retrieved on:

Monday, March 20, 2023

Opportunely, the addendum reiterates that despite the consequences of the unfortunate failure of the US financial institutions Silvergate and Signature Banks, the suitor remains wholly committed to concluding the Equity Investment promptly with RevoluGROUP.

Key Points:

Opportunely, the addendum reiterates that despite the consequences of the unfortunate failure of the US financial institutions Silvergate and Signature Banks, the suitor remains wholly committed to concluding the Equity Investment promptly with RevoluGROUP.
Additionally, the suitors confirmed that the pending final EU transactional compliance approval was, in effect, granted on March 15th, 2023.
Conclusively, per the most recent addendum, the investment proposal is expected to culminate on or before midnight on April 3rd, 2023.
Even so, the Company restates there can still be no assurance that any definitive agreement, tender, or investment will be completed.

Phononic Launches the Active Cooling Solution (ACSTM) Platform to Meet e-grocery Fulfillment Demand

Retrieved on:

Monday, March 20, 2023

Phononic , a global leader in solid state cooling technology, today announced its Active Cooling Solutions platform, a full-service, sustainable solution to solve end-to-end cold chain fulfillment needs for the grocery industry.

Key Points:

Phononic , a global leader in solid state cooling technology, today announced its Active Cooling Solutions platform, a full-service, sustainable solution to solve end-to-end cold chain fulfillment needs for the grocery industry.
“ECONO has experienced first-hand the benefits provided by Phononic’s cooling solution in support of our e-grocery fulfillment initiatives.
Phononic’s ACS platform addresses this gap – providing on-demand cooling and freezing on order through-put achieving unprecedented energy savings,” said Dana Krug, SVP at Phononic.
Phononic will also be joining partners Kalypso/Rockwell Automation and stow Robotics in their booths to discuss more and showcase the ACS platform in action.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on:

Monday, March 20, 2023

ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points:

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
Owner or controller of interests and short positions disclosed, if different from 1(a)
The naming of nominee or vehicle companies is insufficient.
For a trust, the trustee(s), settlor and beneficiaries must be named.
If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
For an opening position disclosure, state the latest practicable date prior to the disclosure
In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on:

Friday, March 17, 2023

ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points:

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
Owner or controller of interests and short positions disclosed, if different from 1(a)
The naming of nominee or vehicle companies is insufficient.
For a trust, the trustee(s), settlor and beneficiaries must be named.
If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
For an opening position disclosure, state the latest practicable date prior to the disclosure
In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on:

Thursday, March 16, 2023

Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, ACT, IRISH, Disclosure, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points:

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
(a) Full name of discloser:
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient.
For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
(d) Status of person making the disclosure:
Person acting in concert with the offeree (namely, a sibling of a director of the offeree)
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on:

Thursday, March 16, 2023

ACT, IRISH, Disclosure, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points:

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
Owner or controller of interests and short positions disclosed, if different from 1(a)
The naming of nominee or vehicle companies is insufficient.
For a trust, the trustee(s), settlor and beneficiaries must be named.
If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
For an opening position disclosure, state the latest practicable date prior to the disclosure
In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.